| HOME >> BIOLOGY >> TECHNOLOGY |
Combination vaccines to pace pediatric productsAmong vaccines for children, sales will be affected by the expiration of patent protection for many of the most widely used vaccines. This has encouraged producers to develop several new combination vaccines, which will serve to maintain the value of products while decreasing the burden of multiple individual injections. Traditional DTaP (diphtheria, tetanus, pertussis) vaccines are being supplemented by products for Hepatitis B and polio or Haemophilus b. Also being developed are vaccines to address a wider range of bacterial serotypes, as with Wyeth's blockbuster PREVNAR7, which has been expanded to address 13 serotypes and which is recommended as a supplement for children who already received the earlier vaccine. Relatively new vaccines, such as that for Rotavirus, continue to mature and to reach greater immunization coverage.
Many new therapeutic vaccines showing promiseVaccine demand will be spurred considerably by a number of therapeutic vaccines for cancer that are nearing completion of clinical trials and are poised for FDA approval. There are currently 50 cancer vaccines in phase III or later trials, and the activity surrounding cancer vaccine development is expected to continue at a high pace. Also showing promise are vaccines being developed for RSV, HIV and Alzheimer's Disease. Similarly, a range of vaccines for travel, developing countries and biodefense are in the pipeline, including prophylactics for malaria, hemorrhagic fevers, West Nile virus and plague.
Study coverageThis new industry study presents historical demand data (1999, 2004 and 2009) plus forecasts for 2014 and 2019 by major and minor product group. The study also considers market environment factors, details industry structure, evaluates company market share and profiles 17 industry participants.
INTRODUCTION vi
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |